{
  "pmcid": "12140551",
  "sha256": "e8148bb99ca6a7c034b2863728ab197788cef30fd2853da2285c5b3f199d1aa9",
  "timestamp_utc": "2025-11-09T15:31:38.092770+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.689534883720931,
    "reading_ease": 51.12271317829459,
    "word_count": 344
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "In this phase III randomized controlled multicenter trial (the SCANDIUM trial)"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "The planned accrual was 90 patients randomized 1:1 to receive a one-time treatment with IHP or best alternative care."
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with previously untreated isolated uveal melanoma liver metastases were included between 2013 and 2021"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized 1:1 to receive a one-time treatment with IHP or best alternative care"
      },
      "Objective": {
        "score": 1,
        "evidence": "To investigate overall survival (OS) and health-related quality of life (HRQOL) of first-line isolated hepatic perfusion (IHP) compared to best alternative care for patients with uveal melanoma liver metastases."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was the 24-month OS rate"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "randomized 1:1"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "87 patients randomized to the IHP group [43 patients; 41 (89%) received IHP] or the control group (44 patients)"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "The intention-to-treat population included 87 patients"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "median progression-free survival was 7.4 months in the IHP group compared with 3.3 months in the control group, with a hazard ratio of 0.21 (95% CI, 0.12â€“0.36)"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 18,
    "max_score": 25
  }
}